Expedited Development Enabled by RMAT and Breakthrough Therapy StatusClinical Trial Initiation in 2026, FDA Approval Target ...
The field of immunology of ageing is rapidly evolving, with T cells playing a pivotal role in maintaining immune competence and overall organismal ...
Plants form a critical model for understanding regulated cell death (RCD) as part of their sophisticated immune responses. In the ongoing evolutionary arms ...
Francis Medical designed its Vanquish system with needle guidance and hands-free stabilization for vapor ablation of the ...
The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and ...
An experimental gene therapy seems to slow the progression of Huntington’s disease by about 75 per cent, and researchers are ...
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to ...
Destination Charged on MSN
Honda recalls 2025 CR-V e:FCEV over fuel cell stack coolant leak risk
Honda has filed a safety recall with the National Highway Traffic Safety Administration (NHTSA) affecting certain 2025 model ...
Hypertrophic chondrocytes are deeply involved in the growth of mammalian bones. Researchers find that these cells transform ...
CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R.
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the ...
Kyverna plans to submit mivocabtagene autoleucel to the FDA for approval in the first half of 2026. If approved, it would be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback